
Novartis rated Hold with 12% downside risk amid near-term product pressure and long-term pipeline growth potential.
Novartis is rated Hold with a 12-month price target of $141.81, suggesting a 12% downside from current levels. The company faces near-term challenges on some products, but its drug development pipeline could support growth over the longer term. Valua...





